Clinical trial
A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection
NCT02450331 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- October 5, 2015
- Completion date
- June 14, 2022
- Enrollment
- 809 (actual)
- Sites
- 186
Conditions
As the registry lists them; a condition with its own page is linked.